ReviewInfectious diseases and therapy2017
Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases.
Review in Infectious diseases and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of respiratory syncytial virus vaccines.The Cochrane database of systematic reviews · 2025Pooled it
- Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.BMC infectious diseases · 2024Pooled it
- Burden, risk factors, and outcomes respiratory syncytial virus (RSV) infection in pediatric intensive care units in Türkiye (RSVP Study 2020-2024).BMC pediatrics · 2026Article
- Review
- Respiratory Syncytial Virus Incidence in Young Children in the United States: Impact of Methodologies and Patient Characteristics.Influenza and other respiratory viruses · 2025Article
- Inpatient service utilization amongst infants diagnosed with Respiratory Syncytial Virus infection (RSV) in the United States.PloS one · 2025Observational
- Respiratory syncytial virus: A new era.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children.World journal of pediatrics : WJP · 2024Review
- Association between prenatal and neonatal risk factors and development of bronchiolitis in early life.Asia Pacific allergy · 2023Article
- Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019.PloS one · 2023Article
- Impact of RSV test positivity, patient characteristics, and treatment characteristics on the cost of hospitalization for acute bronchiolitis in a French university medical center (2010-2015).Frontiers in pediatrics · 2023Article
- The HRA2pl fusion peptide exertsFrontiers in cellular and infection microbiology · 2023Article
- The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review.Infection and drug resistance · 2023Review
- Risk factors associated with severe disease in respiratory syncytial virus infected children under 5 years of age.Frontiers in pediatrics · 2022Article
- Burden of illness in infants and young children hospitalized for respiratory syncytial virus: A rapid review.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2021Article
- The Burden of Respiratory Syncytial Virus in Children Under 2 Years of Age in a Rural Community in Maharashtra, India.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States.Infectious diseases and therapy · 2021Review
- Current State of Respiratory Syncytial Virus Disease and Management.Infectious diseases and therapy · 2021Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionREGAL (RSV Evidence-a Geographical Archive of the Literature) has provided a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This review covers the risk and burden of RSV infection in children with underlying medical conditions or chronic diseases (excluding prematurity and congenital heart disease).
methodsA systematic review of publications between January 1, 1995 and December 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials.gov was supplemented by papers identified by the authors through March 2017. Studies reporting data for hospital visits/admissions for RSV infection as well as studies reporting RSV-associated morbidity and mortality were included. Study quality and strength of evidence (SOE) were graded.
resultsA total of 2703 studies were identified and 58 were included. Down syndrome, irrespective of prematurity and congenital heart disease (moderate SOE), immunocompromised children (low SOE), cystic fibrosis (low SOE), and neurologic conditions (low SOE) were associated with a significantly increased risk of RSV hospitalization. A number of other congenital malformations and chronic conditions were also associated with severe RSV disease (low SOE). In general, pre-existing disease was also a predisposing factor for RSV-related mortality (low SOE).
conclusionSevere RSV infection in infants and young children with underlying medical conditions or chronic diseases poses a significant health burden. Further studies are needed to fully quantify the epidemiology, burden and outcomes in these populations, in particular RSV-attributable mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.